HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

512.773

+16.0313.23%

Number of Gainers:28

Number of Losers:3

Number of Flat:2

PE:- -

High:514.048

Open:496.742

Low:493.725

Close:496.742

Volume:116.33M

Turnover:3.44B

Market Cap:328.03B

Float Cap:291.45B

Loading ...

ETF Market Wrap (Aug 25): Interim Results Validate Innovative Drug Sector Rally While Gold's Pullback Caps Mining Stock Gains

午后市场反弹，A股主要指数表现分化：农业和医药板块领涨，市场成交额达1.8万亿元

A-share Market Close | Indices Diverge While Stocks Rise Broadly; Small Appliances, Pharma, and Agriculture Lead Gains, Precious Metals Decline

Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth

Sweden's Isofol Medical Reports no Q2 Revenue, Net Loss Widens

Everest Med Surges Over 17% in Afternoon Trade as Core Drug Nefecon Drives Strong Revenue Growth

Midday Market Snapshot: Hang Seng Index Slips 0.25% in Morning Session, Mainland Property Stocks Rally Broadly

Interim Results Analysis: PEIJIA-B's Core AR Product Exceeds Expectations, Reinforcing Profitability Signals and Investment Certainty

RemeGen Swings to Profit in H1 as Revenue Surges Fivefold

MT Newswires Live

Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases

THOMSON REUTERS

Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases

Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia

THOMSON REUTERS

What Does The Future Hold For Ascentage Pharma Group International (HKG:6855)? These Analysts Have Been Cutting Their Estimates

Simply Wall St.

Jacobio Pharmaceuticals Appoints Xiaojie Wang as Vice Chairperson

mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence

BRII-B (02137) Buys Back 60,000 Shares for HK$60,300 on August 24

Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

Brii Biosciences Files HKEX Next-Day Disclosure, Lifts Share Capital by 255,793 Shares

和誉-B计划将公司名称更新为“和誉医药有限责任公司”

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":512.7729,"timestamp":1787645292709,"preClose":496.74203,"halted":0,"volume":116328866,"delay":0,"changeRate":0.032272,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":16.030853,"latestTime":"08-25 16:00:00","open":496.74203,"high":514.04803,"low":493.72525,"amount":3439884927.5,"amplitude":0.040912,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787707800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787621400000,1787630400000],[1787634000000,1787644800000]],"pbRate":3.998291,"peRate":-88.309654,"turnoverRate":0.00416,"increases":25,"decrements":5,"flats":3,"marketCap":328025308208,"floatMarketCap":291448018096},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":514.04803,"amplitude":0.040912,"preClose":496.74203,"low":493.72525,"pbRate":"3.998291","latestPrice":512.7729,"volume":116328866,"delay":0,"open":496.74203,"prevYearClose":556.26263,"prevWeekClose":506.075,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":502.603,"twentyDayClose":487.408,"sixtyDayClose":544.023,"secType":"PLATE","market":"HK","turnoverRate":0.00416,"peRate":-88.309654,"marketCap":328025308208,"floatMarketCap":291448018096,"timestamp":1787645292709,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":28,"down":3,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1125535292","title":"ETF Market Wrap (Aug 25): Interim Results Validate Innovative Drug Sector Rally While Gold's Pullback Caps Mining Stock Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1125535292","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125535292?lang=en_us&edition=fundamental","pubTime":"2026-08-25 16:40","pubTimestamp":1787647236,"startTime":"0","endTime":"0","summary":"Hong Kong's stock market experienced narrow oscillations today, with all three major indices closing slightly lower. The release of interim results has provided solid validation for the innovative...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GBUG","FGDL","IGLD","BGLD","RING","VGFPF","FDN","GOAU","BK1574","XLBI","AAAU","GDXD","06978","DGP","UGL","SGDM","BK4550","BK4207","BK4588","GLDY","GLDM","LNGR","DGZ","PYZ","IAUI","GDXY","DUST","FGLD","GDXW","IBBQ","NANR","BK4504","DBC","GOLY","OUNZ","GLD","EPU","YGLD","GDXJ","SGOL","BK1161","GDX","KGLD","BAR","PALL","USG","PHYS","JNUG","IAU","UGLD","BEGS","GDXU","BTGD","BK4535","GLL","DZZ","DULL","IAUM","MGCmain","CEF","SGDJ","GDE","159992","NUGT","GLTR","SHNY","JDST","UYM","02840","CMDT","159562","GLDW","BK4585","CERY","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176665557","title":"午后市场反弹，A股主要指数表现分化：农业和医药板块领涨，市场成交额达1.8万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176665557","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176665557?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:38","pubTimestamp":1787643538,"startTime":"0","endTime":"0","summary":"A股三大主要股指于8月25日集体低开。早盘期间，市场在低位震荡，上证指数一度翻红。午后市场出现快速拉升，三大股指全面转涨后进入震荡模式。盘面上，CRO、生物育种、数字货币、离境退税、短剧游戏、AI应用、智能驾驶、商业航天、机器人以及培育钻石等概念板块涨幅居前；与此同时，贵金属和基本金属板块则领跌市场。截至收盘，上证综指上涨0.19%，报3889.44点；深证成指下跌0.35%，报13745.87点...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["399300","83130","09939","82846","02846","159982","BK1147","BK1515","BK1161","159938","83188","BK1574","03188","07233","02827","03130"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175416480","title":"A-share Market Close | Indices Diverge While Stocks Rise Broadly; Small Appliances, Pharma, and Agriculture Lead Gains, Precious Metals Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=1175416480","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175416480?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:26","pubTimestamp":1787642782,"startTime":"0","endTime":"0","summary":"On August 25th, China's three major A-share indices closed mixed, with the Shanghai Composite Index posting a slight gain, the ChiNext Index falling 1%, and a broad rally across most stocks in the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159041","83188","159982","02846","YSAG","03130","BK1574","82846","03188","BK1515","83130","BK1161","07233","DBP","02827","159938","09939","399300","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143863458","title":"Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1143863458","media":"Stock News","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143863458?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:00","pubTimestamp":1787641221,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) climbed more than 6% in early trading, last up 3.82% at HK$33.7, with turnover reaching HK$12.45 million.On the news front, Hang Seng Indexes Company recently announced the results...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","BK1574","09637","BK4588","KCAI","BK1161","09939","159938","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662786704","title":"Sweden's Isofol Medical Reports no Q2 Revenue, Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2662786704","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662786704?lang=en_us&edition=fundamental","pubTime":"2026-08-25 14:09","pubTimestamp":1787638155,"startTime":"0","endTime":"0","summary":"Sweden's Isofol Medical reports no Q2 revenue, net loss widensOverviewSweden clinical stage biotech reported no Q2 revenue and posted a net lossCompany continued clinical development of arfolitixorin,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M04N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181738748","title":"Everest Med Surges Over 17% in Afternoon Trade as Core Drug Nefecon Drives Strong Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1181738748","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181738748?lang=en_us&edition=fundamental","pubTime":"2026-08-25 14:00","pubTimestamp":1787637630,"startTime":"0","endTime":"0","summary":"Shares of EVEREST MED (01952) extended their gains sharply in the afternoon session, with the stock climbing 17.24% to HK$36.46 at the time of writing, on trading volume of HK$831.8 million.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01952","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139947123","title":"Midday Market Snapshot: Hang Seng Index Slips 0.25% in Morning Session, Mainland Property Stocks Rally Broadly","url":"https://stock-news.laohu8.com/highlight/detail?id=1139947123","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139947123?lang=en_us&edition=fundamental","pubTime":"2026-08-25 12:08","pubTimestamp":1787630920,"startTime":"0","endTime":"0","summary":"Hong Kong stocks opened the session with a mixed tone, as the benchmark Hang Seng Index eased 64 points, or 0.25%, to settle at 25,453 points by the midday break. The Hang Seng Tech Index followed...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002821","LU0588546209.SGD","BK1523","MCHmain","BK1240","HHImain","BK1589","03088","LU1166156734.SGD","BK1191","01918","HTImain","KBDCY","601869","BK1198","06869","SG9999006597.SGD","07500","07552","BK1544","BK1610","BK1521","HK0000320264.USD","513600","02007","BK1574","03423","06821","03067","02610","03033","BK1161","HK0000306701.USD","03330","06693","BK1555","03419","HK0000320223.HKD","HK0000306685.HKD","BK1149","02276","BK1506","BK1507","BK1576","09088","03115","03347","BK1222","LU0702159343.USD","BK1172","BK1141","01952","03417","82800","83115","03032","BK1170","LU0307460666.USD","02837","03037","01548","07300","BK1175","02833","300347","09115","BK1592","00148","NGCRY","HSImain","01167","00081","07200","HSI","02800","09067","CTRYY","FPA","07226","LU0702159699.USD","03918","BK1583","HSTECH","600988"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114204276","title":"Interim Results Analysis: PEIJIA-B's Core AR Product Exceeds Expectations, Reinforcing Profitability Signals and Investment Certainty","url":"https://stock-news.laohu8.com/highlight/detail?id=1114204276","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114204276?lang=en_us&edition=fundamental","pubTime":"2026-08-25 09:02","pubTimestamp":1787619757,"startTime":"0","endTime":"0","summary":"During the first half of this year, Hong Kong-listed pharmaceutical and medical device stocks underwent a phase of valuation digestion alongside an industrial logic reshuffle, marked by notable...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1100","159891","METV","09996","BK1583","BK4213","LNGX","AR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662026272","title":"RemeGen Swings to Profit in H1 as Revenue Surges Fivefold","url":"https://stock-news.laohu8.com/highlight/detail?id=2662026272","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662026272?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:36","pubTimestamp":1787618181,"startTime":"0","endTime":"0","summary":"RemeGen  posted an attributable profit of 4.66 billion yuan in the first half of 2026, rebounding from an attributable loss of 449.57 billion yuan a year ago.Earnings per share came in at 8.32 yuan, compared with a loss per share of 0.83 yuan a year earlier, according to a Monday filing with the Hong Kong Exchange.Revenue surged year over year to 5.85 billion yuan from 1.09 billion, the biopharmaceutical company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","09995","FCA","BK1574","LU1064131003.USD","LU2148510915.USD","LU2488822045.USD","BK1161","688331","LU1969619763.USD","LU2328871848.SGD","BK1583","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662025552","title":"Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2662025552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662025552?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:30","pubTimestamp":1787617800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUABJPBPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1191","06996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179996720","title":"Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1179996720","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179996720?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:04","pubTimestamp":1787612662,"startTime":"0","endTime":"0","summary":"Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06996","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201482","title":"Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201482","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201482?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:42","pubTimestamp":1787611365,"startTime":"0","endTime":"0","summary":"Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseasesAntengene secured Australian HREC clearance for its Phase 1 ATTRACT trial of ATG-201 in B-cell-mediat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL84Czw1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","BK1574","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201488","title":"Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201488?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:42","pubTimestamp":1787611362,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0US:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","06996","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662202735","title":"What Does The Future Hold For Ascentage Pharma Group International (HKG:6855)? These Analysts Have Been Cutting Their Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2662202735","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662202735?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:07","pubTimestamp":1787609228,"startTime":"0","endTime":"0","summary":"Today is shaping up negative for Ascentage Pharma Group International ( HKG:6855 ) shareholders, with the analysts...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/what-does-the-future-hold-for-ascentage-pharma-group-interna","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/what-does-the-future-hold-for-ascentage-pharma-group-interna","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661827033","title":"Jacobio Pharmaceuticals Appoints Xiaojie Wang as Vice Chairperson","url":"https://stock-news.laohu8.com/highlight/detail?id=2661827033","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661827033?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:58","pubTimestamp":1787587095,"startTime":"0","endTime":"0","summary":"BRIEF-Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice ChairpersonAug 24 (Reuters)-Jacobio Pharmaceuticals Group Co Ltd1167.HK:XIAOJIE WANG HAS BEEN APPOINTED  AS THE VICE CHAIRPERSONYUNYAN HU TENDERED RESIGNATION AS EXECUTIVE VICE PRESIDENT OF GROUPFurther company coverage:1167.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L06Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167515089","title":"mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence","url":"https://stock-news.laohu8.com/highlight/detail?id=1167515089","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167515089?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:52","pubTimestamp":1787583127,"startTime":"0","endTime":"0","summary":"On August 19, Moderna and Merck jointly unveiled positive topline results from the global Phase III INTerpath-001 study evaluating the individualized neoantigen mRNA therapy intismeran autogene...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113970719","title":"BRII-B (02137) Buys Back 60,000 Shares for HK$60,300 on August 24","url":"https://stock-news.laohu8.com/highlight/detail?id=1113970719","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113970719?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:34","pubTimestamp":1787582054,"startTime":"0","endTime":"0","summary":"BRII-B (02137) has announced that on August 24, 2026, the company spent HK$60,300 to repurchase 60,000 of its own shares.The buyback reflects the company's ongoing capital management strategy, as it...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02137","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661695272","title":"Press Release: InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2661695272","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661695272?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:32","pubTimestamp":1787581920,"startTime":"0","endTime":"0","summary":"BEIJING, Aug. 24, 2026  -- InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026.InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company's revenue grew by 55.5% year-on-year to RMB 1.1 billion, and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year. These results reflect the successful implementation of the Company's strategy driven by innovation, commercialization and globalization.In the first half of 2026, InnoCare continued to accelerate innovation, achieving a series of key milestones.-- 1 NDA approval: Orelabrutinib was approved in Australia.-- 2 NDA acceptances: The NDA applications for orelabrutinib in primary. immune thrombocytopenia  a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","LU2413666426.HKD","LU1721428933.USD","BK4548","BK1574","BK4199","LU2211817866.USD","BK4121","BK4211","BK4161","BK4533","SLE","LU1093756325.SGD","BK4585","BK4588","IE00BFXG0V08.USD","09969","BK4567","LU1093756168.USD","BK4195","BK1161","PFS","LU0347712357.USD","LU2413666699.HKD","ITP","IE00B5TLWC47.USD","ORR","BK4077","MTD","IE00BYQQ9H92.USD","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661747952","title":"Brii Biosciences Files HKEX Next-Day Disclosure, Lifts Share Capital by 255,793 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2661747952","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661747952?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:18","pubTimestamp":1787581119,"startTime":"0","endTime":"0","summary":"Brii Biosciences files HKEX next-day disclosure, lifts share capital by 255,793 sharesBrii Biosciences filed a next-day disclosure return covering share issuances from option exercises and RSU vesting","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL66JBkW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02137","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189249598","title":"和誉-B计划将公司名称更新为“和誉医药有限责任公司”","url":"https://stock-news.laohu8.com/highlight/detail?id=1189249598","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189249598?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:35","pubTimestamp":1787578523,"startTime":"0","endTime":"0","summary":"和誉-B（02256）近日发布公告，公司董事会已提议对现有名称体系进行调整。根据公告内容，和誉开曼有限责任公司的英文名称将由“Abbisko Cayman Limited”变更为“Abbisko Medicine Co., Ltd.”，同时其中文双重外文名称也将从“和誉开曼有限责任公司”同步更新为“和誉医药有限责任公司”。此次名称变更提案旨在进一步优化公司品牌形象，并更好地反映其业务发展定位。目前该建议已正式提交，尚待相关程序批准后生效。市场投资者可关注后续公告以获取最新进展。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","LU2476274308.USD","IE00B543WZ88.USD","BK1574","LU2488822045.USD","IE00B5MMRT66.SGD","09939","02256","BK1161","LU2778985437.USD","IE00BPRC5H50.USD","BK1515","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":2,"totalSize":299,"code":"91000000","status":"200"}]}}